Several brokerages have updated their recommendations and price targets on shares of Impax Laboratories (NASDAQ: IPXL) in the last few weeks:

  • 8/4/2017 – Impax Laboratories was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Impax Laboratories is now covered by analysts at Canaccord Genuity. They set a “hold” rating and a $19.00 price target on the stock.
  • 7/24/2017 – Impax Laboratories was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong sell” rating. According to Zacks, “Impax’s Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. However, the epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. The company is also taking steps to reduce costs and improve efficiencies, which is estimated to save a total of $130 million by the end of 2019. However, the company’s 2017 earnings guidance is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to hurt revenues. Moreover, the company’s manufacturing facilities had been hampered by quality control issues since 2011 and an inspection had even delayed Rytary’s approval. Impax is also involved in a patent litigation regarding approval of generic version of Rytary. Estimates have been mostly stable ahead of the Q2 results. Impax does not have an impressive record of earnings surprises in the recent quarters.”
  • 7/18/2017 – Impax Laboratories was upgraded by analysts at Piper Jaffray Companies from an “underweight” rating to a “neutral” rating. They now have a $16.00 price target on the stock, up previously from $9.00.
  • 7/17/2017 – Impax Laboratories was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Impax’s epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. Moreover, Impax’s generics pipeline should be able to take advantage of the upcoming patent expirations in the pharma industry. The acquisition of several generic products in Aug 2016 including 15 currently marketed products bode well for Impax. However, the Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. Meanwhile, the company is taking steps to reduce costs and improve efficiencies,which is expected to produce total savings of $130 million by the end of 2019. However, the company’s earnings guidance for 2017 is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to dampen revenues.Estimates have remained mostly stable lately ahead of the Q2 results. Impax has a negative record of earnings surprises in the recent quarters.”
  • 7/17/2017 – Impax Laboratories was given a new $21.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 7/16/2017 – Impax Laboratories was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “hold” rating on the stock.
  • 7/12/2017 – Impax Laboratories was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/11/2017 – Impax Laboratories was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “Impax’s epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. Moreover, Impax’s generics pipeline should be able to take advantage of the upcoming patent expirations in the pharma industry. The acquisition of several generic products in Aug 2016 including 15 currently marketed products bode well for Impax. However, the Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. Meanwhile, the company is taking steps to reduce costs and improve efficiencies,which is expected to produce total savings of $130 million by the end of 2019. However, the company’s earnings guidance for 2017 is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to dampen revenues.Estimates have remained mostly stable lately ahead of the Q2 results. Impax has a negative record of earnings surprises in the recent quarters.”
  • 6/23/2017 – Impax Laboratories had its “hold” rating reaffirmed by analysts at BMO Capital Markets. They now have a $16.00 price target on the stock.
  • 6/16/2017 – Impax Laboratories is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $20.00 price target on the stock.
  • 6/13/2017 – Impax Laboratories had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $15.00 price target on the stock.
  • 6/12/2017 – Impax Laboratories had its “neutral” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $21.00 price target on the stock.

Impax Laboratories, Inc. (IPXL) remained flat at $15.10 on Tuesday. 3,022,930 shares of the company traded hands. Impax Laboratories, Inc. has a 52 week low of $7.75 and a 52 week high of $31.29. The firm has a 50 day moving average of $16.94 and a 200 day moving average of $14.12. The firm’s market capitalization is $1.08 billion.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by $0.01. Impax Laboratories had a positive return on equity of 7.71% and a negative net margin of 71.50%. The company had revenue of $184.40 million for the quarter, compared to analyst estimates of $193.17 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. Impax Laboratories’s revenue for the quarter was down 18.2% on a year-over-year basis. On average, equities analysts anticipate that Impax Laboratories, Inc. will post $0.66 earnings per share for the current fiscal year.

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Receive News & Ratings for Impax Laboratories Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc and related companies with MarketBeat.com's FREE daily email newsletter.